|
MegaPro Biomedical's Cell Therapy Product MPB‑2354 Selected as Top 8 Finalist in the Healthcare Sector at SelectUSA Tech
|
|
MegaPro Biomedical Announces On‑Track Progress of Global Phase III Clinical Trial Program for MPB‑1523
|
|
MegaPro Biomedical Announces Acceptance of Clinical Study Report for MPB‑1734 Phase 1/2a Trial by Taiwan FDA
|
|
MegaPro Biomedical’s Dual Technology Platforms Enter Value‑Harvesting Phase
|
|
MegaPro Biomedical Announces Submission of Pre‑IND Meeting Request for Phase III Clinical Trial of MPB‑1523
|
|
MegaPro Biomedical completed capital increase and introduced new strategic partners
|
|
MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application
|
|
The company passed the approval of the Industrial Bureau of the Ministry of Economic Affairs for the second time as a new biotechnology drug company
|
|
MegaPro Biomedical Held a Pre-Emerging Stock Market Investors Briefing on Oct.14, 2021
|
|
MegaPro Biomedical MPB1523 Nano-MRI contrast agent makes a breakthrough and works with Stanford University in the CAR-T cell therapy experiment, which was published at the WMIC conference
|
